A Phase 4 interventional study of Midodrine Hydrochloride in Hypotension, Orthostatic, sponsored by Shire. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.
Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing midodrine in Hypotension, Orthostatic — none open to participants now, none under way, none of them phase 3. Midodrine · Hypotension, Orthostatic.
Among the 16 studies testing midodrine in Hypotension, Orthostatic, this one is the 4th largest by enrollment, is the only one that started in 1997, is one of 6 in phase 4, and was the 3rd registered.
159 studies on the registry are indexed under Hypotension, Orthostatic; 35 are open to participants now.
Browse Hypotension, Orthostatic studies →None of the 16 studies testing midodrine in Hypotension, Orthostatic is open now. The open studies under Hypotension, Orthostatic, anywhere →
Midodrine: first FDA approval 1996 (PROAMATINE). What it is approved for, and how studies give it, is on its page →
Of the 23 Hypotension, Orthostatic studies recruiting now, 8 (35%) set no upper age limit and 8 (35%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 3 · Phase 4 6
First in 1997; this study’s year is marked. 1 started in 1997.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 28 across 113 interventional studies indexed under Hypotension, Orthostatic.
Median enrollment 42 across the 16 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 16 have an industry lead sponsor. The 9 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
Takeda has 5 studies filed under Hypotension, Orthostatic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing midodrine in Hypotension, Orthostatic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright position) due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathies (i.e. neurogenic orthostatic hypotension). Symptoms of low blood pressure include dizziness, lightheadedness, changes in vision and generalized weakness upon standing. The main effect of the drug being studied is to increase blood pressure in the upright position so symptoms will decrease.
The purpose of this clinical study is to further assess the clinical benefit of midodrine hydrochloride (ProAmatine®), an approved treatment for orthostatic hypotension. During the course of the study, participants will receive either ProAmatine® or a placebo. Assessments will be made using questionnaires that measure symptom and activity levels. Blood pressure in the lying down and standing positions will be measured at each visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Post-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale
Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. Higher scores indicate more severe disease.
Time frame: End of 2-week treatment period
Re-analysis of The Post-treatment Score For Item 1 of The OHSA Scale, Excluding Two Sites
Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. Higher scores indicate more severe disease.
Time frame: End of 2-week treatment period
Post-treatment OHSA Item 1 Score of United States (US) Participants With Mild/Moderate Disease According to The Clinical Global Impressions-Severity (CGI-S) Scale
Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. The results are reported by degree of severity according to the CGI-S scale, which uses 4 categories to describe disease severity: Mild, Moderate, Marked, and Severe. The Item 1 scores reported are grouped for participants with Mild or Moderate disease severity. Higher scores indicate more severe disease.
Time frame: End of 2-week treatment period
Post-treatment OHSA Item 1 Score of US Participants With Marked/Severe Disease According to The CGI-S Scale
Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. The results are reported by degree of severity according to the CGI-S scale, which uses 4 categories to describe disease severity: Mild, Moderate, Marked, and Severe. The Item 1 scores reported are grouped for participants with Marked or Severe disease severity. Higher scores indicate more severe disease.
Time frame: End of 2-week treatment period
Change From Baseline in The OHSA Items 2 Through 6 Scores
Items 2 through 6 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of the following symptoms whenever he or she was standing and that improved when he or she sat down or laid down: Item 2 addresses problems with vision (blurring, seeing spots, tunnel vision, etc); Item 3, weakness; Item 4, fatigue; Item 5, trouble concentrating; and Item 6, head or neck discomfort. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.
Time frame: From the time of titration until the end of treatment
Change From Baseline in The OHSA Composite Symptom Score
The OHSA composite symptom score was calculated by taking the average of the ratings for the symptoms present at Baseline. Participants were asked to rate symptoms by using a 0-10 scale (0 meaning not bothered and 10 meaning the worst). For subsequent visits, only those symptoms present at Baseline were scored. In this manner, a score was produced that represents the severity (and subsequent change in severity) of the patient's neurogenic OH symptoms, regardless of how many symptoms are presented at Baseline. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.
Time frame: From the time of titration until the end of treatment
Change From Baseline in The Orthostatic Hypotension Daily Activity Scale (OHDAS) Items 1 Through 4 Scores
The OHDAS had 4 items that asked the patient to give a graduated score from 0 (no limitation due to OH) to 10 (complete limitation due to OH). Item 1 addressed activities that required standing for a short time; Item 2, activities that required standing for a long time; Item 3, activities that required walking for a short time; and Item 4, activities that required walking for a long time. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.
Time frame: From the time of titration until the end of treatment
Change From Baseline in The Orthostatic Hypotension Global Daily Activity Score
The OHDAS global daily activity score was calculated as the average of all daily activity item scores. The OHDAS had 4 items that asked the patient to give a graduated score from 0 (no limitation due to OH) to 10 (complete limitation due to OH) to activities that required standing for a short time, standing for a long time, walking for a short time, walking for a long time. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.
Time frame: From the time of titration until the end of treatment
Percent of Participants Scored as Improved on The Clinician Version of The Clinical Global Impressions Improvement (CGI-I) Scale
The CGI-I is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Clinical Global Impressions ratings are completed with respect to neurogenic OH symptoms. A value of 0 was used if the investigator or patient assessment was not performed. The improved category is made up of patients who were evaluated as very much improved, much improved, or slightly improved for the classification of "Overall Improvement." The CGI-I was completed at Visit 5 (Period 2) and Visit 6 (study completion).
Time frame: From the time of titration until the end of treatment
Percent of Participants Scored as Improved on The Patient Version of The CGI-I Scale
The CGI-I is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Clinical Global Impressions ratings are completed with respect to neurogenic OH symptoms. A value of 0 was used if the investigator or patient assessment was not performed. The improved category is made up of patients who were evaluated as very much improved, much improved, or slightly improved for the classification of "Overall Improvement." The CGI-I was completed at Visit 5 (Period 2) and Visit 6 (study completion).
Time frame: From the time of titration until the end of treatment
Change From Baseline in Standing Blood Pressure (BP)
Standing BP was measured at Visit 5 (Period 2) and Visit 6 (study completion) and compared to measurements taken at Visit 3A (titration). Standing BP was measured 3 minutes after the patient rose from the supine position or as soon as the patient indicated they needed to sit down. If the patient indicated he or she needed to sit down, the BP measurement was taken while in the standing position, before the patient sat down.
Time frame: From the time of titration until the end of treatment
Change From Baseline in Supine BP
Supine BP was measured at Visit 5 (Period 2) and Visit 6 (study completion) and compared to measurements taken at Visit 3A (titration). Supine BP was measured after the patient had been in the supine position for 5 minutes.
Time frame: From the time of titration until the end of treatment
Change From Baseline in Short Form-36 (SF-36) Version 2 Health Survey Questionnaire Scores
The SF-36 consists of 36 items in eight domains: physical functioning, general health, role-physical, bodily pain, vitality, social functioning, role-emotional, and mental health. Version 2 references "one week ago" for some questions. Raw scale scores for the SF-36 were transformed to a 0-100 scale with a higher score indicating a better quality of life. A positive change from baseline indicates that symptoms have improved. The SF-36 was completed at Visit 5 (Period 2) and Visit 6 (study completion) and compared to the score from Visit 3A (titration).
Time frame: From the time of titration until the end of treatment
Test Reliability of the Intent-to-Treat (ITT) Population
Item 1 of the OHSA, the OHSA composite score, and the OHDAS global daily activity score were analyzed for test-retest reliability as a measure of validity. Test-retest reliability is the Pearson product-moment correlation coefficient calculated between OHQ scores at Visit 3A (baseline measure) and OHQ scores at Visit 5 for the subjects who received Placebo during Randomization Period 1.
Time frame: From the time of titration until the end of treatment
Responsiveness of the Intent-to-Treat (ITT) Population
Item 1 of the OHSA, the OHSA composite score, and the OHDAS global daily activity score were analyzed for responsiveness as a measure of validity. Assuming that subjects who received Placebo during Randomization Period 1 are stable between Visit 3A and Visit 5, and using them as the stable subjects, responsiveness was calculated as \[(OH CFB in Midodrine group)-(OH CFB in Placebo group)\]/(SD of OH CFB in Placebo group), where CFB is change from baseline, SD is the standard deviation of OH CFB of the stable subjects; the value reported is the quotient of this equation.
Time frame: From the time of titration until the end of treatment
Convergent Validity of the Intent-to-Treat (ITT) Population
Item 1 of the OHSA and the OHSA composite score were analyzed for convergent validity with the CGI-I-Clinician scores. The change from baseline in the CGI-I scores are correlated with the OHSA Item 1 score change from baseline and the OHSA composite score change from baseline for the subjects in the ITT population. Values shown are Spearman correlation coefficients.
Time frame: From the time of titration until the end of treatment
| Milestone | All Enrolled Participants | Midodrine/Placebo | Placebo/Midodrine |
|---|---|---|---|
| Started | 140 | 0 | 0 |
| Completed | 136 | 0 | 0 |
| Not completed | 4 | 0 | 0 |
| Milestone | All Enrolled Participants | Midodrine/Placebo | Placebo/Midodrine |
|---|---|---|---|
| Started | 136 | 0 | 0 |
| Completed | 136 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | All Enrolled Participants | Midodrine/Placebo | Placebo/Midodrine |
|---|---|---|---|
| Started | 0 | 45 | 60 |
| Completed | 0 | 45 | 59 |
| Not completed | 0 | 0 | 1 |
| Milestone | All Enrolled Participants | Midodrine/Placebo | Placebo/Midodrine |
|---|---|---|---|
| Started | 0 | 45 | 59 |
| Completed | 0 | 44 | 59 |
| Not completed | 0 | 1 | 0 |
Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. Higher scores indicate more severe disease.
| scores on a scale | Midodrine HCl | Placebo |
|---|---|---|
| Post-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale | 4.1 ± 2.9 | 5.2 ± 2.7 |
Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. Higher scores indicate more severe disease.
| scores on a scale | Midodrine HCl | Placebo |
|---|---|---|
| Re-analysis of The Post-treatment Score For Item 1 of The OHSA Scale, Excluding Two Sites | 4.3 ± 2.93 | 5.1 ± 2.76 |
Items 2 through 6 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of the following symptoms whenever he or she was standing and that improved when he or she sat down or laid down: Item 2 addresses problems with vision (blurring, seeing spots, tunnel vision, etc); Item 3, weakness; Item 4, fatigue; Item 5, trouble concentrating; and Item 6, head or neck discomfort. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.
| scores on a scale | Midodrine HCl | Placebo |
|---|---|---|
| Item 2, n= 103, 103 | -1.2 ± 2.5 | -0.2 ± 2.3 |
| Item 3, n=103, 103 | -1.3 ± 3.2 | -0.4 ± 2.5 |
| Item 4, n=103, 103 | -1.2 ± 3.2 | -0.4 ± 2.6 |
| Item 5, n=102, 102 | -0.4 ± 2.7 | 0.0 ± 2.2 |
| Item 6, n=102, 102 | -0.8 ± 2.6 | -0.5 ± 2.1 |
The OHSA composite symptom score was calculated by taking the average of the ratings for the symptoms present at Baseline. Participants were asked to rate symptoms by using a 0-10 scale (0 meaning not bothered and 10 meaning the worst). For subsequent visits, only those symptoms present at Baseline were scored. In this manner, a score was produced that represents the severity (and subsequent change in severity) of the patient's neurogenic OH symptoms, regardless of how many symptoms are presented at Baseline. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.
| scores on a scale | Midodrine HCl | Placebo |
|---|---|---|
| Change From Baseline in The OHSA Composite Symptom Score | -1.3 ± 2.5 | -0.54 ± 1.952 |
The OHDAS had 4 items that asked the patient to give a graduated score from 0 (no limitation due to OH) to 10 (complete limitation due to OH). Item 1 addressed activities that required standing for a short time; Item 2, activities that required standing for a long time; Item 3, activities that required walking for a short time; and Item 4, activities that required walking for a long time. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.
| scores on a scale | Midodrine HCl | Placebo |
|---|---|---|
| Item 1, n=102, 101 | -1.1 ± 2.90 | -0.4 ± 1.95 |
| Item 2, n=98, 99 | -1.8 ± 3.14 | -0.6 ± 2.41 |
| Item 3, n=100, 101 | -1.1 ± 2.71 | -0.2 ± 2.16 |
| Item 4, n=89, 90 | -1.3 ± 3.31 | -0.5 ± 2.57 |
The OHDAS global daily activity score was calculated as the average of all daily activity item scores. The OHDAS had 4 items that asked the patient to give a graduated score from 0 (no limitation due to OH) to 10 (complete limitation due to OH) to activities that required standing for a short time, standing for a long time, walking for a short time, walking for a long time. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.
| scores on a scale | Midodrine HCl | Placebo |
|---|---|---|
| Change From Baseline in The Orthostatic Hypotension Global Daily Activity Score | -1.4 ± 2.6 | -0.4 ± 1.9 |
The CGI-I is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Clinical Global Impressions ratings are completed with respect to neurogenic OH symptoms. A value of 0 was used if the investigator or patient assessment was not performed. The improved category is made up of patients who were evaluated as very much improved, much improved, or slightly improved for the classification of "Overall Improvement." The CGI-I was completed at Visit 5 (Period 2) and Visit 6 (study completion).
| percent of participants | Midodrine HCl | Placebo |
|---|---|---|
| Percent of Participants Scored as Improved on The Clinician Version of The Clinical Global Impressions Improvement (CGI-I) Scale | 73.1 | 45.2 |
The CGI-I is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Clinical Global Impressions ratings are completed with respect to neurogenic OH symptoms. A value of 0 was used if the investigator or patient assessment was not performed. The improved category is made up of patients who were evaluated as very much improved, much improved, or slightly improved for the classification of "Overall Improvement." The CGI-I was completed at Visit 5 (Period 2) and Visit 6 (study completion).
| percent of participants | Midodrine HCl | Placebo |
|---|---|---|
| Percent of Participants Scored as Improved on The Patient Version of The CGI-I Scale | 62.5 | 50.0 |
Standing BP was measured at Visit 5 (Period 2) and Visit 6 (study completion) and compared to measurements taken at Visit 3A (titration). Standing BP was measured 3 minutes after the patient rose from the supine position or as soon as the patient indicated they needed to sit down. If the patient indicated he or she needed to sit down, the BP measurement was taken while in the standing position, before the patient sat down.
| mmHg | Midodrine HCl | Placebo |
|---|---|---|
| Systolic Pressure | 10.7 ± 21.68 | 2.8 ± 19.55 |
| Diastolic Pressure | 5.9 ± 14.46 | 1.5 ± 13.03 |
Supine BP was measured at Visit 5 (Period 2) and Visit 6 (study completion) and compared to measurements taken at Visit 3A (titration). Supine BP was measured after the patient had been in the supine position for 5 minutes.
| mmHg | Midodrine HCl | Placebo |
|---|---|---|
| Systolic Pressure | 7.6 ± 22.76 | -0.9 ± 15.74 |
| Diastolic Pressure | 3.4 ± 11.89 | 0.3 ± 10.35 |
The SF-36 consists of 36 items in eight domains: physical functioning, general health, role-physical, bodily pain, vitality, social functioning, role-emotional, and mental health. Version 2 references "one week ago" for some questions. Raw scale scores for the SF-36 were transformed to a 0-100 scale with a higher score indicating a better quality of life. A positive change from baseline indicates that symptoms have improved. The SF-36 was completed at Visit 5 (Period 2) and Visit 6 (study completion) and compared to the score from Visit 3A (titration).
| scores on a scale | Midodrine HCl | Placebo |
|---|---|---|
| General Health | 1.97 ± 7.801 | 1.59 ± 6.027 |
| Physical Functioning | 1.99 ± 8.255 | 1.71 ± 8.034 |
Item 1 of the OHSA, the OHSA composite score, and the OHDAS global daily activity score were analyzed for test-retest reliability as a measure of validity. Test-retest reliability is the Pearson product-moment correlation coefficient calculated between OHQ scores at Visit 3A (baseline measure) and OHQ scores at Visit 5 for the subjects who received Placebo during Randomization Period 1.
| correlation coefficient | ITT Population |
|---|---|
| OHSA Item 1 | 0.53 |
| OHSA Composite Score | 0.61 |
| OHDAS Global Daily Activity Score | 0.66 |
Item 1 of the OHSA, the OHSA composite score, and the OHDAS global daily activity score were analyzed for responsiveness as a measure of validity. Assuming that subjects who received Placebo during Randomization Period 1 are stable between Visit 3A and Visit 5, and using them as the stable subjects, responsiveness was calculated as \[(OH CFB in Midodrine group)-(OH CFB in Placebo group)\]/(SD of OH CFB in Placebo group), where CFB is change from baseline, SD is the standard deviation of OH CFB of the stable subjects; the value reported is the quotient of this equation.
| quotient | ITT Population |
|---|---|
| OHSA Item 1 | -0.4099 |
| OHSA Composite Score | -0.4014 |
| OHDAS Global Daily Activity Score | -0.4903 |
Item 1 of the OHSA and the OHSA composite score were analyzed for convergent validity with the CGI-I-Clinician scores. The change from baseline in the CGI-I scores are correlated with the OHSA Item 1 score change from baseline and the OHSA composite score change from baseline for the subjects in the ITT population. Values shown are Spearman correlation coefficients.
| correlation coefficient | ITT Population |
|---|---|
| OHSA Item 1, n=103 | 0.36 |
| OHSA Composite Score, n=102 | 0.38 |
Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. The results are reported by degree of severity according to the CGI-S scale, which uses 4 categories to describe disease severity: Mild, Moderate, Marked, and Severe. The Item 1 scores reported are grouped for participants with Mild or Moderate disease severity. Higher scores indicate more severe disease.
| scores on a scale | Midodrine HCl | Placebo |
|---|---|---|
| Post-treatment OHSA Item 1 Score of United States (US) Participants With Mild/Moderate Disease According to The Clinical Global Impressions-Severity (CGI-S) Scale | 4.4 ± 2.97 | 3.8 ± 2.63 |
Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. The results are reported by degree of severity according to the CGI-S scale, which uses 4 categories to describe disease severity: Mild, Moderate, Marked, and Severe. The Item 1 scores reported are grouped for participants with Marked or Severe disease severity. Higher scores indicate more severe disease.
| scores on a scale | Midodrine HCl | Placebo |
|---|---|---|
| Post-treatment OHSA Item 1 Score of US Participants With Marked/Severe Disease According to The CGI-S Scale | 4.7 ± 2.90 | 6.1 ± 2.60 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Screening/Washout | — | 1/140 (0.7%) | 12/140 (8.6%) |
| Titration | — | 4/136 (2.9%) | 42/136 (30.9%) |
| Midodrine HCl | — | 0/104 (0%) | 22/104 (21.2%) |
| Placebo | — | 1/105 (1%) | 23/105 (21.9%) |
| Follow-up | — | 5/140 (3.6%) | 23/140 (16.4%) |
| Event | Screening/Washout | Titration | Midodrine HCl | Placebo | Follow-up |
|---|---|---|---|---|---|
| Neck painMusculoskeletal and connective tissue disorders | 0/140 | 0/136 | 0/104 | 1/105 | 0/140 |
| Blindness corticalEye disorders | 0/140 | 1/136 | 0/104 | 0/105 | 0/140 |
| Therapeutic agent poisoningInjury, poisoning and procedural complications | 0/140 | 1/136 | 0/104 | 0/105 | 0/140 |
| Convulsions NOSNervous system disorders | 0/140 | 1/136 | 0/104 | 0/105 | 0/140 |
| Orthostatic hypotensionVascular disorders | 1/140 | 1/136 | 0/104 | 0/105 | 1/140 |
| Cardiac arrestCardiac disorders | 0/140 | 0/136 | 0/104 | 0/105 | 1/140 |
| Colitis NOSGastrointestinal disorders | 0/140 | 0/136 | 0/104 | 0/105 | 1/140 |
| Gastrointestinal haemorrhage NOSGastrointestinal disorders | 0/140 | 0/136 | 0/104 | 0/105 | 1/140 |
| Injury NOSInjury, poisoning and procedural complications | 0/140 | 0/136 | 0/104 | 0/105 | 1/140 |
| Parkinson's disease NOSNervous system disorders | 0/140 | 0/136 | 0/104 | 0/105 | 1/140 |
| Event | Screening/Washout | Titration | Midodrine HCl | Placebo | Follow-up |
|---|---|---|---|---|---|
| Headache NOSNervous system disorders | 1/140 | 13/136 | 6/104 | 7/105 | 5/140 |
| Pruritus NOSSkin and subcutaneous tissue disorders | 0/140 | 11/136 | 8/104 | 8/105 | 9/140 |
| ParaesthesiaNervous system disorders | 0/140 | 10/136 | 5/104 | 5/105 | 3/140 |
| Hypertension NOSVascular disorders | 4/140 | 9/136 | 3/104 | 2/105 | 2/140 |
| DizzinessNervous system disorders | 3/140 | 7/136 | 3/104 | 5/105 | 5/140 |
| Urinary tract infection NOSInfections and infestations | 5/140 | 6/136 | 1/104 | 1/105 | 7/140 |
The intent-to-treat (ITT) population, defined as all patients who were randomly assigned to treatment in the study and have at least one post-randomization Orthostatic Hypotension Questionnaire (OHQ) measurement.
| Age, Continuous(years) | Midodrine/Placebo | Placebo/Midodrine | Total |
|---|---|---|---|
| Mean | 62.0 ± 14.22 | 62.2 ± 14.43 | 62.2 ± 14.27 |
| Sex: Female, Male(Participants) | Midodrine/Placebo | Placebo/Midodrine | Total |
|---|---|---|---|
| Female | 23 | 24 | 47 |
| Male | 22 | 35 | 57 |
Ran from Dec 1997 to primary completion in Nov 1999, 23 months.
Results were first posted in May 2015, 15 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Midodrine